Lataa...
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state
Metformin is widely used to treat hyperglycemia in individuals with type 2 diabetes. Recently the LKB1/AMP-activated protein kinase (LKB1/AMPK) pathway was proposed to mediate the action of metformin on hepatic gluconeogenesis. However, the molecular mechanism by which this pathway operates had rema...
Tallennettuna:
| Päätekijät: | , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Clinical Investigation
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2898585/ https://ncbi.nlm.nih.gov/pubmed/20577053 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI40671 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|